Outcomes after 18 months of eliglustat therapy in treatment‐naïve adults with G aucher disease type 1: The phase 3 ENGAGE trial

Eliglustat, an oral substrate reduction therapy, is a first-line treatment for adults with Gaucher disease type 1 (GD1) who are poor, intermediate, or extensive CYP2D6 metabolizers (>90% of patients). In the primary analysis of the Phase 3 ENGAGE trial (NCT00891202), eliglustat treatment for 9 month... View More